慢性丁型肝炎抗病毒治疗策略的研究进展

Antiviral treatment strategies for chronic hepatitis D:current clinical practice and clinical trials

慢性丁型肝炎是一种临床结局严重的慢性病毒性肝炎,目前聚乙二醇干扰素α是较为广泛使用的治疗方案,但总体疗效欠佳。近年来,针对多靶点的新药物处于研发中,包括欧盟药监系统有条件批准的bulevirtide。本文通过对抗丁型肝炎病毒药物研发的政策和方案的研究进展进行综述,以探讨有可能对今后临床实践有影响的抗丁型肝炎策略。

Chronic hepatitis D would lead to worse clinical outcome.Pegylated interferon alpha is currently recommended by AASLD, EASL, APASL and WHO, as well as suggested as standard-of care by US FDA.Up to now, a few new drugs are on clinical trial targeted on different mechanism in hepatitis D virus life cycle, including bulevirtide(a inhibitor on virus entry).We here summarize strategy for new regimens clinical trial and potential clinical practice in future.